Clinical TrialsThe advancement of RAD 204 into a first-in-human Phase I trial in non-small cell lung cancer is a significant development for Radiopharm Theranostics.
Market StrategyThe launch of American Depository Shares, with plans for a secondary listing on Nasdaq, positions Radiopharm for broader market exposure.
Therapeutic PipelineRadiopharm Theranostics has focused its therapeutic pipeline on biologically validated targets that have seen limited or no use in radiopharmaceuticals, which is designed to de-risk development and limit competition.